After scanning several human oral cancer samples, we found that in some cases, the distribution and amount of IL-6 in stage I, II, III oral cancer and normal tissues did not show obvious differences. The reason for this phenomenon was unknown. We inferred that IL-6 was involved in many physiological and pathological processes, including Covid-19 infection, trauma, infection, inflammation, and the development of malignant tumors. Therefore, the expression level of IL-6 could be interfered with by many factors related to the patient's healthy state. Therefore, the accuracy was not high enough if we used IL-6 as the only biomarker for distinguishing oral cancer and normal tissues. Therefore, we still require more evidence and samples to evaluate the precision of using the IL-6 protein as the only biomarker for oral cancer detection. Since the IL-6 overexpression could be found in many diseases, we investigated another biomarker, EGFR, to scan with SECM. The pretreated human oral cancer samples were labeled with EGFR antibody and secondary antibody with HRP. Figures and illustrate the schematic representation of the x-line scan of different oral tissue samples using the soft probe. Figure shows the normal submandibular glands labeled with the x-line scans of the EGFR antibody and the second-stage cancer tissues of the maxillary and third-stage cancer tissues of the floor of the mouth. Figure presents the x-line scans of normal tongue tissue, secondstage cancer tissue of the upper jaw, and first-stage cancer tissue of the lower lip.